2037 results about "Treatment regimen" patented technology

A transdermal patch system configured as a patch or pump assembly may be placed into contact upon a skin surface to transport drugs or agents transdermally via any number of different mechanisms such as microporous membranes, microneedles, in-dwelling catheters, etc. The assembly may enclose or accommodate a reservoir configured as an elongate microchannel to contain the drug or agent suspended in a fluid vehicle. The reservoir may also be fluidly coupled via microchannels to transport the drugs into or against an underlying skin surface as driven or urged via a pump and controlled by an electronic control circuitry which may be programmed to affect any number of treatment regimens.

The present invention provides treatment regimens for treating diseased prostate tissue, including the steps of chemically ablating prostate tissue and coadministering an antiandrogen. In some embodiments, prostate tissue is chemically ablated by injection of ethanol, or an injectable gel comprising ethanol, into prostate tissue. Steroidal and non-steroidal antiandrogens are suitable antiandrogens. One suitable non-steroidal antiandrogen is bicalutamide. The treatment regimen is suitable for treatment of prostate tissue diseases including benign prostatic hyperplasia and prostatic carcinoma. The invention further provides a treatment regimen for treating benign prostatic hyperplasia, including the steps of damaging prostate tissue and coadministering an antiandrogen. Also provided by the present invention is a kit for treating a human male, including a means for necrosing prostate tissue, an antiandrogen drug, and a means for administering the antiandrogen drug. A kit including a first surgical device for delivering a chemoablation fluid to prostate tissue transurethrally, an antiandrogen drug such as bicalutamide, and a second surgical device for administering the antiandrogen drug, is further provided.

Provided is an improved treatment for Parkinson's Disease where the efficacy of L-Dopa treatment is increased by including gene therapy in the treatment regimen. The combination therapy results in long-term improvements in response to L-Dopa and diminished side effects caused by L-Dopa.

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

A method and system for treating tissue with a combined therapy profile is disclosed. In one exemplary embodiment, ultrasound energy is used to treat numerous depths of tissue within a region of interest and the spatial and temporal properties of the ultrasound energy are varied for more effective treatment. The method and system of the present invention are configured to treat all of the tissue from the surface on down and not spare intervening tissue.

A treatment Device is provided which enables a Doctor/Pharmacist to provide patient specific instructions in a textual format to a patient. The instructions are converted by a speech synthesizer provided in the Device into an audibly perceptible format. When configured as a hand-held unit, the Device may store a plurality of medications. Upon activation or automatically, instructions saved in the device are communicated to a patient/user via various audible, visual and/or tactile indicators. The instructions are provided to the device via a Platform which enables Doctors and Pharmacists input instructions into the Platform, which, via a Platform interface, are saved into a storage device provided in the Device. In an additional embodiment, a removable medication dispensing cartridge is provided which facilitates the controlled and automatic dispensing of a medication to a patient based upon a treatment schedule. Patient compliance information with a treatment schedule may be provided by the Device.

The invention provides methods for predicting responsiveness to TNFα inhibitors in a subject suffering from an autoimmune disorder, such as rheumatoid arthritis. The methods involve assaying for expression of one or more biomarkers in the subject that are predictive of responsiveness to TNFα inhibitors. A preferred biomarker of the invention is CD11c. The methods can further comprise selecting a treatment regimen with a TNFα inhibitor in an autoimmune disorder subject based upon expression of the biomarker(s) in the subject. The methods can further comprise administering a TNFα inhibitor to the subject according to the selected treatment regimen. Kits that include means for measuring expression of one or more biomarkers that are predictive of responsiveness to TNFα inhibitors for an autoimmune disorder are also provided. Methods of preparing and using databases, and computer program products therefore, for selecting an autoimmune disorder subject for treatment with a TNFα inhibitor are also provided.

The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

The invention encompasses systems, methods, and apparatus for predicting and monitoring an individual's response to a therapeutic regimen. The invention includes multiple virtual patients, an associating subsystem operable to associate the subject with one or more of the virtual patients, and a simulation engine operable to apply one or more experimental protocols to the one or more virtual patients identified with the subject to generate a set of outputs. The set of outputs can represent therapeutic efficacy, identify biomarkers for monitoring therapeutic efficacy, or merely report the status of the biological system as it represents a particular individual

The present invention relates to a system and method for facilitating and managing health care between a medical provider and a patient. In one aspect, the system and method includes providing a patient having a first criteria, which includes a medical symptom. The system and method also include selecting a subset of medical providers having expertise in treating the medical symptom, generating a care request to obtain a treatment proposal for the medical symptom of the patient, and updating the care request with medical information associated with the medical symptom. The system and method further include receiving at least one treatment proposal of the medical symptom from the medical providers and selecting a treatment proposal of the medical symptom from the medical providers.

Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.

The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to rule in or out SIRS, or for differentiating sepsis, severe sepsis, septic shock and/or MODS from each other and/or from non-infectious SIRS.

Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower gastrointestinal tract of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.

The present invention relates to the identification and use of gene expression profiles with clinical relevance to prostate cancer. In particular, the invention provides the identity of genes whose expression, at the transcriptional and protein levels, is correlated with prostate cancer progression. Methods and kits are described for using these gene expression profiles in the study and/or diagnosis of prostate cancer diseases, in the prediction of prostate cancer progression, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that target these genes or their protein products, in particular for the development of therapeutics for modulating prostate cancer progression.

The present invention relates to pharmaceutical compositions, which provide controlled release of a drug. The compositions are suitable for continuous administration as they remain effective throughout the treatment regimen. The present invention also relates to the use of the compositions for preparation of a medicament for continuous treatment of an individual.

A mobile station and methods are disclosed for diagnosing and modeling site specific effluent treatment facility requirements to arrive at a treatment regimen and/or proposed commercial plant model idealized for the particular water/site requirements. The station includes a mobile platform having power intake, effluent intake and fluid outflow facilities and first and second suites of selectably actuatable effluent pre-treatment apparatus. An effluent polishing treatment array is housed at the station and includes at least one of nanofiltration, reverse osmosis and ion-exchange stages. A suite of selectively actuatable post-treatment apparatus is housed at the station. Controls are connected at the station for process control, monitoring and data accumulation. A plurality of improved water treatment technologies is also disclosed. The modeling methods include steps for analyzing raw effluent to be treated, providing a field of raw effluent condition entry values and a field of treated effluent condition goals entry values, and utilizing said fields to determine an initial treatment model including a selection of, and use parameters for, treatment technologies from the plurality of down-scaled treatment technologies at the facility, the model dynamically and continuously modifiable during treatment modeling.

The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range.

The invention provides a computer network comprising a first computer and one or more second computers that are in electronic communication with each other. The first computer is associated with a first health care facility and has instructions for retrieving, over a network, one or more data structures for a patient enrolled in a health care program. The one or more data structures for the patient collectively comprise (i) a patient identifier, (ii) a molecular profile from a biological specimen obtained from the patient at the first health care facility; and (iii) a clinical characterization of the patient that was made at the first health care facility. The first computer has instructions for retrieving, over the network connection, one or a plurality of treatment regimens that are deemed suitable for the patient based upon the molecular profile and the clinical characterization of the patient. The one or more second computers are at one or more locations other than the first health care facility and have one or more data structures for each patient in a plurality of patients enrolled in the health care program

Systems and/or methods for assessing the sleep quality of a patient in a sleep session are provided. Data is collected from the patient and/or physician including, for example, sleep session data in the form of one or more physiological parameters of the patient indicative of the patient's sleep quality during the sleep session, a subjective evaluation of sleep quality, etc.; patient profile data; etc. A sleep quality index algorithm, which optionally may be an adaptive algorithm, is applied, taking into account some or all of the collected data. Sleep quality data may be presented to at least the patient, and it may be displayed in any suitable format (e.g., a format useful for the patient to be appraised on the progress of the treatment, a format useful for a sleep clinician to monitor progress and/or assess the effectiveness of differing treatment regimens, etc).